Morepen Laboratories Ltd. (MOREPENLAB) Share Price Hits New 52-Week High
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Morepen Laboratories Ltd. Share Price reached a fresh 52-week high of Rs 76.11, rising 9.97% today. The market cap stands at Rs 3,160.6 crore.
Morepen Laboratories Ltd. Share Price has surged to a new 52-week high, reaching Rs 76.11, marking a significant increase of 9.97% from the previous close of Rs 69.21. The company’s market capitalisation is now Rs 3,160.6 crore. This milestone highlights the stock’s strong performance in the market, drawing attention from investors and analysts alike. The stock opened at Rs 73.01 and reached a high of Rs 77.55 during the day, indicating robust trading activity.
Morepen Laboratories Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 76.11 |
| Previous Close | Rs 69.21 |
| Today's Change | +Rs 6.9 (+9.97%) |
| Day Open | Rs 73.01 |
| Fresh 52-Week High | Rs 77.55 |
| Day Low | Rs 73.01 |
| Current Volume | 17,70,031 |
| Turnover | Rs 13.47 crore |
| Market Capitalisation | Rs 3,160.6 crore |
Morepen Laboratories Ltd. (MOREPENLAB) traded at Rs 76.11. versus the previous close of Rs 69.21, a rise of 9.97%. The stock opened at Rs 73.01, reached Rs 77.55, touched Rs 73.01. Reported volume was 17,70,031.
Today, Morepen Laboratories Ltd. Share Price opened at Rs 73.01 and quickly climbed to a high of Rs 77.55, marking a fresh 52-week high. The stock closed at Rs 76.11, reflecting a day change of Rs 6.9 or 9.97%. The day’s low was the opening price of Rs 73.01, and the turnover reached Rs 13.47 crore with a volume of 1,770,031 shares. This significant price movement and high trading volume underscore the stock’s current market momentum.
Morepen Laboratories Ltd. (MOREPENLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 3,160.6 crore |
| P/E Ratio | 30.21x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
Morepen Laboratories Ltd. was valued at a P/E ratio of 30.21x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.21x |
| Benchmark Median P/E | 21.71x |
| Benchmark Average P/E | 71.67x |
| Benchmark P/E Range | 0x to 3,385.56x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.75% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 3,160.6 crore |
| Benchmark Median Market Cap | Rs 136.63 crore |
Morepen Laboratories Ltd. (MOREPENLAB) is classified under sector: Healthcare.
Morepen Laboratories Ltd. (MOREPENLAB) has a P/E ratio of 30.21x, which is above the benchmark median of 21.71x, a difference of +39.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Morepen Laboratories Ltd. (MOREPENLAB) has a ROE of -2.89%, which is below the benchmark median of 10.75%, a difference of -126.88%. Morepen Laboratories Ltd. (MOREPENLAB) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,945.17 | 30.21 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,652.68 | 39.86 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,608.51 | 63.2 | 10 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,457.9 | 32.25 | 6.65 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,451.51 | 164.6 | 3.04 | 13.9 | 12.97 |
Morepen Laboratories Ltd. (MOREPENLAB) has a P/E ratio of 30.21x compared with the displayed peer median of 39.86x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Morepen Laboratories Ltd. (MOREPENLAB) has a market capitalisation of Rs 3,160.6 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Morepen Laboratories Ltd.
- Strong price action with a fresh 52-week high.
- Mixed fundamental indicators with a low P/B ratio.
- Significant market cap within the Healthcare sector.
- Comparison with peers reveals valuation insights.
About Morepen Laboratories Ltd.
Morepen Laboratories Ltd. operates in the Healthcare sector, focusing on pharmaceuticals and healthcare products. The company is known for its range of products in the pharmaceuticals and drugs industry, catering to various healthcare needs. With a significant market presence, Morepen Laboratories continues to expand its product offerings and market reach, contributing to its position within the sector.
Track Morepen Laboratories Ltd. Share Price on Univest
Use Morepen Laboratories Ltd. (MOREPENLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Morepen Laboratories Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest for comprehensive analysis and informed decision-making.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Morepen Laboratories Ltd.?
Ans. The current share price of Morepen Laboratories Ltd. is Rs 76.11, marking a 9.97% increase from the previous close of Rs 69.21. The stock moved 9.97% during the session. The intraday range extended from Rs 73.01 to Rs 77.55.
What is the market capitalisation of Morepen Laboratories Ltd.?
Ans. Morepen Laboratories Ltd. has a market capitalisation of Rs 3,160.6 crore, indicating its substantial size within the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.21x.
How does Morepen Laboratories Ltd.'s P/E ratio compare to the sector?
Ans. Morepen Laboratories Ltd.'s P/E ratio of 30.21 is above the sector median of 21.71 but below the average of 71.67, suggesting a moderate valuation. The company trades at a P/E ratio of 30.21x.
What are the ROE and ROCE of Morepen Laboratories Ltd.?
Ans. Morepen Laboratories Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, indicating challenges in generating returns. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.75%.
How does Morepen Laboratories Ltd.'s market cap compare to its peers?
Ans. Morepen Laboratories Ltd.'s market cap of Rs 3,160.6 crore is larger than Dishman Carbogen but smaller than Kwality Pharmaceuticals. The company operates in the Healthcare sector. Its P/E ratio is 30.21x.
What is the P/B ratio of Morepen Laboratories Ltd.?
Ans. The P/B ratio of Morepen Laboratories Ltd. is 0.44, significantly lower than the sector median of 1.9, indicating a potentially undervalued position. The company trades at a P/E ratio of 30.21x.
How does Morepen Laboratories Ltd.'s P/B ratio compare to its peers?
Ans. Morepen Laboratories Ltd.'s P/B ratio of 0.44 is notably lower than Kwality Pharmaceuticals' 8.11, suggesting a more conservative valuation. The company trades at a P/E ratio of 30.21x. Its P/B ratio is 0.44x.
